JPH06166609A - Whitening and beautifying agent - Google Patents
Whitening and beautifying agentInfo
- Publication number
- JPH06166609A JPH06166609A JP3231640A JP23164091A JPH06166609A JP H06166609 A JPH06166609 A JP H06166609A JP 3231640 A JP3231640 A JP 3231640A JP 23164091 A JP23164091 A JP 23164091A JP H06166609 A JPH06166609 A JP H06166609A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- pigmentation
- whitening
- minutes
- tyrosinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、ウワウルシ又はそのエ
キスを有効成分とする美白剤又は色素沈着症改善剤に関
する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening agent or an agent for improving pigmentation, which contains a Japanese lacquer tree or its extract as an active ingredient.
【0002】[0002]
【従来の技術】シミ、ソバカス、色黒等の色素沈着症
は、皮膚にメラニン色素が過剰に沈着した疾患である。2. Description of the Related Art Pigmentation diseases such as spots, freckles, and dark skin are diseases in which melanin pigment is excessively deposited on the skin.
【0003】本疾患は、特に、女性にとっては美容上好
ましいものではなく、シミ、ソバカスを改善したり、肌
をより効果的に美白にするものが望まれてきた。This disease is not cosmetically preferable for women, and it has been desired to improve spots, freckles, and effectively whiten the skin.
【0004】前記メラニンは、動植物界に広く分布して
いるが、脊椎動物におけるその生合成については、メラ
ノサイト中の細胞質顆粒メラノソームで、チロシンがチ
ロシナーゼにより酸化されて、ドーパ、ドーパキノン、
インドールキノンを経て生合成されるルートが知られ、
又、本ルートでは、紫外線による自動酸化によってメラ
ニン生成は促進されることが知られている。The melanin is widely distributed in the animal and plant kingdoms. Regarding its biosynthesis in vertebrates, it is a cytoplasmic granular melanosome in melanocytes, in which tyrosine is oxidized by tyrosinase and dopa, dopaquinone,
A route known to be biosynthesized through indole quinone is known,
In addition, it is known that in this route, melanin production is promoted by autoxidation by ultraviolet rays.
【0005】一方、ウワウルシは、尿路防腐薬として用
いられる生薬で、古来より、民間的にはアレルギー性皮
膚炎に用いられている。On the other hand, the Japanese algae is a crude drug used as a urinary tract antiseptic, and has been used for folk allergic dermatitis since ancient times.
【0006】ウワウルシの一成分であるアルブチンにつ
いては、美白効果が知られているが、その美白効果は充
分とは到底いえない。[0006] Arbutin, which is a component of Japanese lacquer, is known to have a whitening effect, but the whitening effect is far from sufficient.
【0007】しかし、ウワウルシ自身については、美白
効果やシミ、ソバカス等の色素沈着症の改善効果は知ら
れていない。[0007] However, regarding the Japanese lacquer itself, the whitening effect and the effect of improving pigmentation such as spots and freckles are not known.
【0008】[0008]
【発明が解決しようとする課題】本発明は、従来、知ら
れている美白剤に比べ、優れた効力を有する美白剤又は
色素沈着症改善剤を提供することを目的とするものであ
る。SUMMARY OF THE INVENTION It is an object of the present invention to provide a whitening agent or a pigmentation ameliorating agent which has superior efficacy as compared with conventionally known whitening agents.
【0009】[0009]
【課題を解決するための手段】本発明者らは、上記の目
的を達成するため、鋭意研究を重ねた結果、ウワウルシ
又はそのエキスが、アルブチンに比べ、優れた美白効果
及び色素沈着症の改善効果を有することを見いだし、本
発明を完成したものである。Means for Solving the Problems As a result of intensive studies to achieve the above-mentioned objects, the present inventors have found that the Japanese lacquer tree or its extract has a superior whitening effect and an improvement in pigmentation disease as compared with arbutin. The present invention has been completed by finding out that it has an effect.
【0010】本発明にかかわる色素沈着症としては、上
記の如く、メラニン色素が皮膚に過剰に沈着した疾患で
あり、その具体例としては、シミ、ソバカス、色黒、ス
テロイド等の薬物による皮膚の黒化症等を挙げることが
できる。As described above, the pigmentation disease according to the present invention is a disease in which melanin pigment is excessively deposited on the skin. Specific examples thereof include skin spots caused by spots, freckles, dark skin and steroids. Examples include melanosis.
【0011】本発明において、ウワウルシのエキスにつ
いては、水、温湯、エタノール、含水エタノール等の通
常生薬エキスの抽出に使用される溶媒を用いて、抽出し
たものや、また、その抽出液から前記溶媒を凍結乾燥、
噴霧乾燥、減圧留去等の方法で除去することにより得ら
れる粉末をも挙げることができる。[0011] In the present invention, as regards the extract of Stelleria vulgaris, the extract obtained by using a solvent usually used for extraction of herbal extracts such as water, warm water, ethanol and hydrous ethanol, and the above-mentioned solvent from the extract. Lyophilize,
The powder obtained by removing by a method such as spray drying or distillation under reduced pressure can also be mentioned.
【0012】本発明のウワウルシ又はそのエキスの投与
方法としては、経口投与、局所投与等種々の方法を挙げ
ることができるが、一般的には、外用剤として皮膚に塗
布することが簡便である。Various methods such as oral administration and topical administration can be mentioned as the administration method of the porcupine or its extract of the present invention, but it is generally convenient to apply it to the skin as an external preparation.
【0013】該外用剤としては、軟膏剤、クリーム、乳
液、リニメント剤、ローション剤等を挙げることができ
る。Examples of the external preparation include ointments, creams, emulsions, liniments, lotions and the like.
【0014】これらの製剤は、ウワウルシの破砕物や前
記のごときウワウルシのエキスの抽出液もしくは粉末
に、適当な添加剤、賦形剤等を混合し、公知の製剤技術
を用いて製造することができる。These preparations may be produced by mixing known additives such as a crushed product of the Japanese porcupine or an extract or powder of the extract of Japanese porcupine with appropriate additives and excipients. it can.
【0015】本発明にかかわるウワウルシ又はそのエキ
スの投与量は、投与方法により異なるが、外用剤として
投与する場合には、皮膚疾患部に前記の如き外用剤を適
当量塗布すれば良い。The dose of the Japanese algae or its extract according to the present invention varies depending on the administration method, but when administered as an external preparation, an appropriate amount of the external preparation as described above may be applied to the skin disease area.
【0016】[0016]
【発明の効果】本発明にかかわるウワウルシ又はそのエ
キスは、シミ、ソバカス、色黒等の色素沈着症の原因で
あるメラニン色素の産生に対して、優れた抑制効果を示
した。EFFECTS OF THE INVENTION The Japanese lacquer tree or its extract according to the present invention showed an excellent inhibitory effect on the production of melanin pigment, which is a cause of pigmentation diseases such as spots, freckles, and dark skin.
【0017】従って、本発明は美白剤及びシミ、ソバカ
ス、色黒等の色素沈着症改善剤として優れたものであ
る。Therefore, the present invention is excellent as a whitening agent and an agent for improving pigmentation disorders such as spots, freckles, and dark skin.
【0018】以下に、参考例、実施例を挙げて、本発明
を更に詳細に説明するが、本発明はこれに限定されるも
のではない。Hereinafter, the present invention will be described in more detail with reference to Reference Examples and Examples, but the present invention is not limited thereto.
【0019】[0019]
【参考例】日局「ウワウルシ」の粗切100 kgに常水1000
lを加え、約30分で90℃となるように昇温し、90〜100
℃で 1時間抽出した後、液温65℃でステンレス製金網
(120 メッシュ)を用いてろ過し、第一抽出液を得た。
残渣に常水1000 lを加え、同様に 1時間抽出した後、液
温65℃でステンレス製金網(120 メッシュ)を用いてろ
過し、第二抽出液を得た。第一抽出液及び第二抽出液を
合わせ、60℃以下で減圧濃縮(減圧度120 mmHg)し、ウ
ワウルシエキス約24.0kgを得た。このウワウルシエキス
に無水エタノール120 l を加え十分撹拌した後、一夜室
温下に放置し、ステンレス製金網(120 メッシュ)を用
いてろ過した。ろ液を、60℃以下で減圧濃縮(減圧度12
0 mmHg)した後、常水約100 l に懸濁し噴霧乾燥し、乾
燥エキスを得た(収量約 12.4 kg)。[Reference example] Roughly cut 100 kg of Japanese urchin "Urushi" to normal water 1000
Add l, raise the temperature to 90 ° C in about 30 minutes, and
After extracting at 1 ° C for 1 hour, the mixture was filtered at a liquid temperature of 65 ° C using a stainless steel wire mesh (120 mesh) to obtain a first extract.
1000 l of ordinary water was added to the residue, and the mixture was extracted for 1 hour in the same manner, and then filtered at a liquid temperature of 65 ° C using a stainless steel wire net (120 mesh) to obtain a second extract. The first extract and the second extract were combined and concentrated under reduced pressure (pressure reduction 120 mmHg) at 60 ° C. or lower to obtain about 24.0 kg of the Japanese lacquer extract. 120 l of absolute ethanol was added to this lacquer extract, and after thoroughly stirring, the mixture was allowed to stand overnight at room temperature and filtered using a stainless steel wire mesh (120 mesh). Concentrate the filtrate under reduced pressure at 60 ° C or lower (degree of vacuum 12
(0 mmHg), then suspended in about 100 l of normal water and spray-dried to obtain a dried extract (yield about 12.4 kg).
【0020】[0020]
1)被験体 ・参考例のウワウルシ抽出乾燥エキス(以下、U-ext と
略す) ・標準品アルブチン 2)試料 ・マッシュルーム由来チロシナーゼ(3870 Units/mg Si
gma 社製)(上記チロシナーゼ 5 mg を10 ml の1/15 M
リン酸緩衝液に用時溶解して用いた。) ・1/15 Mリン酸緩衝液:リン酸一カリウム リン酸二カリウム(上記リン酸一カリウム0.4999 gとリ
ン酸二カリウム0.5214 gを精製水100 mlに溶解して、pH
6.8としたものを用いた。 ・ドーパ:ナカライテスク社製(上記ドーパ 30 mlを1/
15 Mリン酸緩衝液 100mlに用時溶解して用いた。) ・被験体は緩衝液に溶解して用いた。1) Subject ・ Dried extract of Steller's sea urchin extract (hereinafter abbreviated as U-ext) ・ Reference arbutin 2) Sample ・ Mushroom-derived tyrosinase (3870 Units / mg Si
gma) (5 mg of the above tyrosinase was added to 10 ml of 1/15 M
It was dissolved in a phosphate buffer before use.・ 1/15 M Phosphate buffer: monopotassium phosphate dipotassium phosphate (0.4999 g of the above-mentioned monopotassium phosphate and 0.5214 g of dipotassium phosphate were dissolved in 100 ml of purified water to obtain pH.
The one set to 6.8 was used.・ Dopa: manufactured by Nacalai Tesque, Inc.
It was dissolved in 100 ml of 15 M phosphate buffer before use. ) -Subjects were dissolved in a buffer and used.
【0021】実験例 1:チロシナーゼ酵素活性阻害 1-1 実験方法及び結果 H.S. Mason(Biochem.Biophys.Acta.,111,134(1965))、T.
Nagatu(Experientia,28,634(1972)) らの方法に従っ
て、被験液1 mlに酵素チロシナーゼ液(5 mg/10 ml)0.
1 mlと1/15 Mリン酸緩衝液(pH 6.8)0.9 mlを添加し、
25℃、10分間インキュベートした。次に、基質ドーパ溶
液(0.03 % pH 6.8 リン酸緩衝液)l mlを加え、25℃、
5分間インキュベートした。反応後、475 nmにおける吸
光度を測定した(D1)。別に、過熱失活酵素を使って同
様の操作を行い、吸光度(D2)、試料無添加におけるド
ーパクロム生成量(D3)を測定した。 阻害率(%)=[D3−(D1−D2)]/D3×100 結果を以下の表に示す。Experimental Example 1: Inhibition of tyrosinase enzyme activity 1-1 Experimental method and results HS Mason (Biochem. Biophys. Acta., 111, 134 (1965)), T.
According to the method of Nagatu (Experientia, 28,634 (1972)), the enzyme tyrosinase solution (5 mg / 10 ml) was added to 1 ml of the test solution.
Add 1 ml and 0.9 ml of 1/15 M phosphate buffer (pH 6.8),
Incubated at 25 ° C for 10 minutes. Next, add 1 ml of the substrate dopa solution (0.03% pH 6.8 phosphate buffer) at 25 ° C,
Incubated for 5 minutes. After the reaction, the absorbance at 475 nm was measured (D 1 ). Separately, the same operation was performed using a heat-inactivating enzyme, and the absorbance (D 2 ) and the amount of dopachrome produced (D 3 ) in the absence of the sample were measured. Inhibition rate (%) = [D 3 − (D 1 −D 2 )] / D 3 × 100 The results are shown in the table below.
【0022】[0022]
【表1】 上記結果より明らかな如く、U-ext はチロシナーゼ酵素
活性を極めて微量で抑制した。一方、U-ext より単離し
たアルブチンもチロシナーゼ酵素活性を有意に抑制し
た。しかし、U-ext のチロシナーゼ酵素阻害活性は、ア
ルブチンのそれよりも約1000倍強力であった。[Table 1] As is clear from the above results, U-ext suppressed the tyrosinase enzyme activity in a very small amount. On the other hand, arbutin isolated from U-ext also significantly suppressed tyrosinase enzyme activity. However, the tyrosinase enzyme inhibitory activity of U-ext was about 1000 times stronger than that of arbutin.
【0023】実験例 2:チロシナーゼ酵素活性阻害によ
るメラニン産生に及ぼす影響 2-1 実験方法及び結果 H.S. Mason(Biochem.Biophys.Acta.,111,134(1965))、T.
Nagatu(Experientia,28,634(1972)) らの方法に従っ
て、被験液1 mlに酵素チロシナーゼ液( 5mg/10 ml)0.
1 mlと1/15 Mリン酸緩衝液(pH 6.8)0.9 mlを添加し、
25℃、10分間インキュベートした。次に、基質ドーパ溶
液(0.03 % pH 6.8 リン酸緩衝液)l mlを加え、25℃、
30分間あるいは60分間インキュベートした。1N塩酸 0.2
ml で反応を停止させ、3000 rpm、15分間の遠心分離に
て沈渣を得た。この沈渣をさらに6N塩酸 1 ml ×1 回、
蒸留水 2 ml ×2 回の遠心分離にて洗浄後、2 mlのソル
エン 350(パッカード社製)に溶解した。溶解しにくい
ときは、ソニケーターにて強制溶解させた。溶解液の吸
光度を400 nmで測定し、標準品メラニンの吸光度曲線か
らメラニン量を算出した。結果を以下の表に示す。Experimental Example 2: Effect on melanin production by inhibition of tyrosinase enzyme activity 2-1 Experimental method and results HS Mason (Biochem.Biophys.Acta., 111,134 (1965)), T.
According to the method of Nagatu (Experientia, 28, 634 (1972)), the enzyme tyrosinase solution (5 mg / 10 ml) was added to 1 ml of the test solution.
Add 1 ml and 0.9 ml of 1/15 M phosphate buffer (pH 6.8),
Incubated at 25 ° C for 10 minutes. Next, add 1 ml of the substrate dopa solution (0.03% pH 6.8 phosphate buffer) at 25 ° C,
Incubated for 30 minutes or 60 minutes. 1N hydrochloric acid 0.2
The reaction was stopped with ml, and the precipitate was obtained by centrifugation at 3000 rpm for 15 minutes. This sediment is further added with 6N hydrochloric acid 1 ml × 1 time,
After washing with 2 ml of distilled water and centrifugation twice, it was dissolved in 2 ml of Solen 350 (manufactured by Packard). When it was difficult to dissolve, it was forcibly dissolved with a sonicator. The absorbance of the solution was measured at 400 nm, and the amount of melanin was calculated from the absorbance curve of standard melanin. The results are shown in the table below.
【0024】[0024]
【表2】 上記結果に示したごとく、U-ext は微量でメラニン産生
を有意に抑制したが、アルブチンには全く抑制作用が認
められなかった。[Table 2] As shown in the above results, U-ext significantly suppressed melanin production in a trace amount, but arbutin had no inhibitory effect.
【0025】実験例 3:ドーパクロムからの自動酸化阻
害によるメラニン産生に及ぼす影響 3-1 実験方法及び結果 H.S. Mason(Biochem.Biophys.Acta.,111,134(1965))、T.
Nagatu(Experientia,28,634(1972)) らの方法に従っ
て、酵素チロシナーゼ液(5 mg/10 ml)0.1 mlと1/15 M
リン酸緩衝液(pH 6.8)0.9 mlを添加し、25℃、10分間
インキュベートした。次に、基質ドーパ溶液(0.03 % p
H 6.8 リン酸緩衝液)l mlを加え、25℃、5分間インキ
ュベートし、さらに被験液 1 ml を加え、30分間あるい
は45分間インキュベートした。1N塩酸 0.2 ml で反応を
停止させ、3000 rpm、15分間の遠心分離にて沈渣を得
た。この沈渣をさらに6N塩酸 1 ml ×1 回、蒸留水 2 m
l ×2 回の遠心分離にて洗浄後、2 mlのソルエン 350
(パッカード社製)に溶解した。溶解しにくいときは、
ソニケーターにて強制溶解させた。溶解液の吸光度を40
0 nmで測定し、標準品メラニンの吸光度曲線からメラニ
ン量を算出した。結果を以下の表に示す。Experimental Example 3: Effect on melanin production by inhibition of autoxidation from dopachrome 3-1 Experimental method and results HS Mason (Biochem.Biophys.Acta., 111,134 (1965)), T.M.
According to the method of Nagatu (Experientia, 28,634 (1972)) et al., 0.1 ml of enzyme tyrosinase solution (5 mg / 10 ml) and 1/15 M
0.9 ml of phosphate buffer (pH 6.8) was added, and the mixture was incubated at 25 ° C for 10 minutes. Next, the substrate dopa solution (0.03% p
H 6.8 phosphate buffer) (1 ml) was added, the mixture was incubated at 25 ° C. for 5 minutes, 1 ml of the test solution was further added, and the mixture was incubated for 30 minutes or 45 minutes. The reaction was stopped with 0.2 ml of 1N hydrochloric acid, and the precipitate was obtained by centrifugation at 3000 rpm for 15 minutes. This sediment was further added with 6N hydrochloric acid 1 ml × 1 time, distilled water 2 m
l x 2 times of centrifugation and then 2 ml of Solen 350
(Made by Packard). If it is difficult to dissolve,
It was forcibly dissolved with a sonicator. The absorbance of the solution is 40
The measurement was performed at 0 nm, and the melanin amount was calculated from the absorbance curve of the standard melanin. The results are shown in the table below.
【0026】[0026]
【表3】 上記結果に示したごとく、U-ext はドーパクロムが産生
されたころ、即ち、チロシナーゼによる酸化でなく、自
動酸化がメラニン産生にかかわる頃に添加してもメラニ
ン産生を有意に抑制したが、アルブチンにはその抑制作
用が認められなかった。[Table 3] As shown in the above results, U-ext significantly suppressed melanin production even when dopachrome was produced, that is, when oxidization by tyrosinase, but not by autooxidation involved in melanin production, significantly suppressed melanin production. Did not show its inhibitory effect.
【0027】《結論》以上の結果から明らかな如く、ウ
ワウルシエキスは、アルブチンに比べ、優れたチロシナ
ーゼ酵素活性阻害作用及びメラニン産生抑制作用を示し
た。従って、ウワウルシ又はそのエキスが、アルブチン
に比べ、優れた美白効果及びシミ、ソバカス、色黒等の
色素沈着症に対する改善効果を有することが確認され
た。<Conclusion> As is clear from the above results, the Japanese lacquer extract showed superior tyrosinase enzyme activity inhibitory activity and melanin production inhibitory activity as compared with arbutin. Therefore, it was confirmed that the Japanese lacquer tree or its extract has an excellent whitening effect and an effect of improving pigmentation diseases such as spots, freckles, and black skin, as compared with arbutin.
Claims (3)
る美白剤1. A whitening agent containing a Japanese lacquer tree or its extract as an active ingredient.
る色素沈着症改善剤2. A pigmentation amelioration agent comprising a Japanese lacquer tree or its extract as an active ingredient.
請求の範囲第2項記載の改善剤3. The improving agent according to claim 2, wherein the pigmentation is a spot or freckles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23164091A JP3167148B2 (en) | 1991-09-11 | 1991-09-11 | Whitening agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23164091A JP3167148B2 (en) | 1991-09-11 | 1991-09-11 | Whitening agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06166609A true JPH06166609A (en) | 1994-06-14 |
JP3167148B2 JP3167148B2 (en) | 2001-05-21 |
Family
ID=16926670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP23164091A Expired - Lifetime JP3167148B2 (en) | 1991-09-11 | 1991-09-11 | Whitening agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3167148B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057840A3 (en) * | 1999-03-26 | 2001-01-11 | Pentapharm Ag | Dermatological topical composition |
JP2002114668A (en) * | 2000-10-11 | 2002-04-16 | Noevir Co Ltd | Skin care preparation |
JP2002519312A (en) * | 1998-06-30 | 2002-07-02 | エイボン プロダクツ インコーポレーテッド | Skin whitening composition |
JP2004083551A (en) * | 2002-07-02 | 2004-03-18 | Kao Corp | Whitening composition |
WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
CN104116951A (en) * | 2014-07-19 | 2014-10-29 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for beautifying and whitening |
-
1991
- 1991-09-11 JP JP23164091A patent/JP3167148B2/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002519312A (en) * | 1998-06-30 | 2002-07-02 | エイボン プロダクツ インコーポレーテッド | Skin whitening composition |
WO2000057840A3 (en) * | 1999-03-26 | 2001-01-11 | Pentapharm Ag | Dermatological topical composition |
JP2002114668A (en) * | 2000-10-11 | 2002-04-16 | Noevir Co Ltd | Skin care preparation |
JP2004083551A (en) * | 2002-07-02 | 2004-03-18 | Kao Corp | Whitening composition |
WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
CN104116951A (en) * | 2014-07-19 | 2014-10-29 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for beautifying and whitening |
Also Published As
Publication number | Publication date |
---|---|
JP3167148B2 (en) | 2001-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003212714A (en) | Topical lightening composition and use thereof | |
US20060216253A1 (en) | Whitening cosmetics containing morus alba extracts | |
JP3800611B2 (en) | Whitening agent or pigmentation ameliorating agent | |
JP5773111B2 (en) | Composition for inhibiting skin pigmentation and use thereof | |
JP3167148B2 (en) | Whitening agent | |
JPH07187988A (en) | Melanism inhibitor, its production and skin-beautifying containing the same cosmetic | |
JP3693754B2 (en) | Tyrosinase activity inhibitor | |
JP3431383B2 (en) | Melanin inhibitor | |
WO2010115472A2 (en) | Topical skin lightening composition | |
KR101095609B1 (en) | Cosmetic composition containing whitening Composition for whitening Skin | |
EP2555745B1 (en) | Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol | |
JP2003516358A (en) | Melanin synthesis inhibitory compound and composition containing the melanin synthesis inhibitory compound | |
KR20190103897A (en) | Composition for whitening comprising fraction of Inula helenium as an active ingredient | |
JP4076477B2 (en) | Skin preparation | |
US8309144B2 (en) | Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition | |
KR101904216B1 (en) | A composition for skin whitening and improving skin wrinkle comprising extracts of jujube seed | |
JP3120087B2 (en) | Hair cosmetics for prevention of gray hair and blackening of gray hair | |
JP2003192564A (en) | Melanogenesis inhibitor | |
KR102416777B1 (en) | Composition comprising Carex scabrifolia extract | |
JPH11189541A (en) | Therapeutic agent for melanogenetic insufficiency | |
KR101724604B1 (en) | Whitening cosmetic composition to the skin containing GSH-MEE(Reduced glutathione monoethyl ester) | |
JP4223723B2 (en) | Melanin production deficiency preventive and therapeutic agent | |
JP6629968B2 (en) | Composition for skin whitening containing Amorphigeni as active ingredient | |
US20100324142A1 (en) | Hydrocortisone derivatives and use thereof for therapeutic or cosmetic indications | |
JP3553179B2 (en) | Whitening agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080309 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090309 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090309 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100309 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100309 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110309 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120309 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120309 Year of fee payment: 11 |